Hepatic artery infusion chemotherapy with systemic capecitabine and camrelizumab for treating unresectable hilar cholangiocarcinoma: An initial investigation of efficacy and safety

• Published in: Journal of cancer research and therapeutics Vol. 20; no. 2; pp. 578 - 583
• Main Authors: Li, Long, Liu, Song, Wang, Qingdong, Wang, Yanhua, Yu, Guangji
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.04.2024; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Edition: 2
• Subjects: Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bile Duct Neoplasms - drug therapy; Bile Duct Neoplasms - pathology; Cancer; Capecitabine; Capecitabine - administration & dosage; Capecitabine - adverse effects; Capecitabine - therapeutic use; Chemotherapy; Cholangiocarcinoma; Cholangiocarcinoma - drug therapy; Cholangiocarcinoma - pathology; Dosage and administration; Evaluation; Female; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Methods; Middle Aged; Original Article; Retrospective Studies; Survival Rate; Treatment Outcome; China; capecitabine; Camrelizumab; hepatic artery infusion chemotherapy; hilar cholangiocarcinoma

ABSTRACT Objective: This study aimed to evaluate the efficacy and safety of sequential treatment of continuous transcatheter hepatic artery infusion chemotherapy (HAIC) with systemic capecitabine monotherapy and camrelizumab for treating unresectable hilar cholangiocarcinoma (HCCA). Methods: This st...